• Press Release

Convalescent Plasma Is A Potentially Effective Treatment Option for Patients Hospitalized With COVID 19, According to Early Data

  • New York, NY
  • (May 22, 2020)

Patients hospitalized with COVID-19 who received convalescent plasma demonstrated improved survival and were more likely than matched control patients to remain the same or have improvements in their supplemental oxygen requirements, according to a study conducted by researchers at the Icahn School of Medicine at Mount Sinai and published today on pre-print server medRxiv. The study details the preliminary outcomes of 39 patients hospitalized at The Mount Sinai Hospital in New York, who were among the very first in the nation to receive convalescent plasma transfusions, compared against a cohort of retrospectively matched controls.

“New York City was among the earliest and hardest hit by the COVID-19 pandemic in the United States, so during the study’s 16-day enrollment period in late March, our Health System had a large, diverse pool of COVID-19 patients from which to draw control patients, allowing us to use an aggressive matching algorithm,” says Nicole Bouvier, MD, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai and co-senior author of the paper. “We are encouraged that our initial assessment offers evidence in support of convalescent plasma as an effective intervention, while remaining mindful that additional studies are needed to confirm these findings and draw more definitive conclusions in different populations.”

For this study, plasma recipients and control patients were 100 percent matched on their supplemental oxygen requirement on day zero, in addition to other baseline demographic factors and comorbidities. Of them, 69.2 percent were receiving high-flow oxygen and 10.3 percent were receiving invasive mechanical ventilation. By day 14, clinical condition had worsened in 18 percent of the plasma patients and 24.3 percent of the control patients. On days one and seven, the plasma group also showed a reduction in the proportion of patients with worsened oxygenation status, but that difference was not statistically significant. As of May 1, 12.8 percent of plasma recipients and 24.4 percent of the 1:4 matched control patients had died, with 71.8 percent and 66.7 percent, respectively, being discharged alive.

Patients were identified as eligible for COVID-19 convalescent plasma transfusion under the criteria established by the U.S. Food and Drug Administration (FDA) single patient emergency investigational new drug process. Plasma recipients were transfused with convalescent plasma from donors with a SARS-CoV-2 anti-spike antibody titer (level) of greater than or equal to 1:320 dilution and all were transfused with two units of convalescent plasma matching the recipient’s blood type.

Importantly, the cohort of matched control patients were retrospectively identified within the hospital’s electronic record database, using an aggressive matching algorithm designed by Mount Sinai biostatisticians that matched the plasma recipients to controls for three levels of patient information: 1) baseline demographics and comorbidities, including age; gender; smoking status; presence of obesity, diabetes, COPD or sleep apnea; and d-dimer and c-reactive protein at admission; 2) day of transfusion data, including supplemental oxygen requirement, length of hospital stay, minimal oxygen saturation, heart rate, respiratory rate, and systolic and diastolic BP;  and 3) time series data up to the day of transfusion, including the use of hydroxychloroquine or azithromycin, intubation status, and, if intubated, duration of intubation. For controls patients, the day of transfusion was defined by the length of stay on which their respective recipient received their transfusion. To confirm the independent effect of convalescent plasma transfusion or improvement in oxygenation and survival, the team conducted a propensity score-matched analysis using The Mount Sinai Hospital’s COVID-19 confirmed patient pool from the same calendar period (March 24 to April 8, 2020). Among the predictors, exact matching was enforced on the administration of hydroxychloroquine and azithromycin, intubation status and duration, length of hospital stay, and oxygen requirement on the day of transfusion.

The COVID-19 pandemic poses an unprecedented challenge, as physicians and scientists struggle in real time to identify effective interventions against SARS-CoV-2 and its complications. The conclusions drawn from these data are not as robust as a prospective, randomized, placebo-controlled study, however this study has the unique strength of propensity score matching, which other case series have lacked.

“The efficacy of passive antibody transfer relies heavily on the quality of the donor convalescent plasma,” says Judith Aberg, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and co-senior author of the paper. “Mount Sinai rapidly developed and clinically deployed an enzyme-linked immunosorbent antibody test (ELISA) to titrate SARS-CoV-2-specific antibodies in serum, enabling our center the unique ability to refer for blood collection only those convalescent donors with the highest plasma antibody levels. We are profoundly grateful for the generosity of thousands of anonymous residents of the tri-state area who recovered from COVID-19 and then volunteered to donate convalescent plasma for the benefit of others.”

“We’ve all experienced losses recently, whether it is our health or our freedom. As we face one of the largest pandemics of mankind, physicians and scientists will continue to unite in our common interests to return to a safe, normal life. It’s not easy, but this is a step forward.”– Sean Liu, MD PhD, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and first author of the paper.  

To support COVID-19 research and response efforts, visit https://www.mountsinai.org/covid19research.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.